Judi Rx Drug Recall Report

JUNE 2026

Welcome to the **Judi Rx Drug Recall Report**. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Judi Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Judi Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. Judi Rx is executing its mission through the deployment of Judi®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. Judi connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **6/17/2026****

Privacy Statement:

Judi Rx, Inc., on behalf of itself and its subsidiaries (including but not limited to Judi Health, LLC and Amino, LLC) ("we," "our," or "us") is committed to ensuring that your privacy is protected. This privacy policy describes the types of information we may collect from you or that you may provide to us and our practices for collecting, using, maintaining, protecting, and disclosing that information. This policy applies to information collected or provided through any services offered on or through judihealth.com such as the member web portal, our care navigation platform, and our mobile application accessible at the Google Play Store and iOS App Store under the name Judi Rx | Judi Health (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
5/27/2026	Class 2	Atomoxetine Hcl 25 Mg Caps	Safecor Health, LLC	64380-0474-01	25530722	A label mix-up. Atomoxetine HCl 25mg Capsule was incorrectly labeled as Atomoxetine HCl 10mg Capsule.
5/27/2026	Class 2	Cimzia (2 Syringe) 200 Mg/Ml Pskt	UCB Biosciences Inc.	50474-0710-79, 50474-0710-80, 50474-0710-81	CVZFW, EXP 2026-JUL-04; CVZYG, EXP 2026-AUG-19; CWSYT, EXP 2026-OCT-22; CWDZY, EXP 2026-NOV-20; CWTSD, EXP 2026-DEC-11; CVTFK, EXP 2026-JUL-04; CVTSN, EXP 2026-AUG-19; CWVGP, EXP 2026-DEC-11; CVWXT, CVWXV, CVWXW, EXP 2026-JUL-04; CWHFF, EXP 2026-OCT-22; CWNDS, EXP 2026-DEC-11	A lack of assurance of sterility.

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
5/27/2026	Class 2	Cimzia-Starter 200 Mg/Ml Pskt	UCB Biosciences Inc.	50474-0710-79, 50474-0710-80, 50474-0710-81	CVZFW, EXP 2026-JUL-04; CVZYG, EXP 2026-AUG-19; CWSYT, EXP 2026-OCT-22; CWDZY, EXP 2026-NOV-20; CWTSD, EXP 2026-DEC-11; CVTFK, EXP.:2026-JUL-04; CVTSN, EXP 2026-AUG-19; CWVGP, EXP 2026-DEC-11; CVWXT, CVWXV, CVWXW, EXP 2026-JUL-04; CWHFF, EXP 2026-OCT-22; CWNDS, EXP 2026-DEC-11	A lack of assurance of sterility.
5/27/2026	Class 2	Erythromycin Base 250 Mg Tabs	Zydus Pharmaceuticals (USA) Inc	70710-1047-03, 70710-1047-01	A) M411146, EXP 08/2026; M502098, M502097, EXP 01/2027; B) M411145, EXP 08/2026	Deviations from Current Good Manufacturing Practices (CGMP) and the presence of an impurity called N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable limit.
5/27/2026	Class 2	Erythromycin Base 500 Mg Tabs	Zydus Pharmaceuticals (USA) Inc	70710-1048-03	A) M411147, EXP 08/2026; M502100, M502099, EXP 01/2027	Deviations from Current Good Manufacturing Practices (CGMP) and the presence of an impurity called N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable limit.
5/27/2026	Class 2	Estradiol 0.25 Mg/0.25gm Gel	ANI Pharmaceuticals, Inc.	70954-0531-20	M251109, EXP NOV 2027	A defective container. Packets were found to be either empty or partially full.
5/27/2026	Class 2	Liraglutide 18 Mg/3ml Sopn	Lupin Pharmaceuticals Inc.	70748-0346-02, 70748-0346-03	A) WB00097, WB00094, WB00088, EXP JUL. 2027; WB00103, EXPIRES: OCT. 2027; WC00016, EXP DEC. 2027; B) WB00098, WB00092, WB00093, EXP JUL. 2027; WB00104, WB00106, WB00105, EXP OCT. 2027	A white thread-like structure found in the cartridge.

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
6/10/2026	Class 2	Amlodipine-Olmesartan 5-40 Mg Tabs	Ascend Laboratories, LLC	67877-0501-30	24123460, EXP OCTOBER 31, 2027	Failure to meet dissolution specifications, resulting in olmesartan medoxomil content below specifications.
6/10/2026	Class 2	Niacin Er (Antihyperlipidemic) 1000 Mg Tbcr	Lannett Company Inc.	62175-0322-46	25282724A, EXP 2027/01	Failure to meet dissolution specifications during 12-month stability testing.
6/17/2026	Class 2	Duloxetine Hcl 30 Mg Cpep	Breckenridge Pharmaceutical, Inc.	51991-0747-10	241180C, EXP APRIL 2027	Deviations from Current Good Manufacturing Practices (CGMP), as an impurity, N-nitroso-duloxetine, was found to exceed the FDA's recommended interim limit.
6/17/2026	Class 2	Duloxetine Hcl 60 Mg Cpep	Breckenridge Pharmaceutical, Inc.	51991-0748-90	A) 241074C, EXP MAY 2027; 240317, 240318, 240315C, 240373C, 240370C, 240375C, 240413C, EXP FEBRUARY 2027; 240316,EXP JANUARY 2027; 232311, EXP NOVEMBER 2026; B) 240978C, 241052C, EXP APRIL 2027	Deviations from Current Good Manufacturing Practices (CGMP), as an impurity, N-nitroso-duloxetine, was found to exceed the FDA's recommended interim limit.
6/17/2026	Class 2	Minocycline Hcl Er 115 Mg Tb24	Ascend Laboratories, LLC	67877-0644-30	25141635, EXP 4/30/2028	Failure to meet dissolution specifications: an out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Atomoxetine Hcl 25 Mg Caps	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220081
Class 2	Cimzia (2 Syringe) 200 Mg/Ml Pskt	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220270
Class 2	Cimzia-Starter 200 Mg/Ml Pskt	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220270
Class 2	Erythromycin Base 250 Mg Tabs	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220051
Class 2	Erythromycin Base 500 Mg Tabs	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220068
Class 2	Estradiol 0.25 Mg/0.25gm Gel	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220258
Class 2	Liraglutide 18 Mg/3ml Sopn	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=219870
Class 2	Amlodipine-Olmesartan 5-40 Mg Tabs	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220060
Class 2	Niacin Er (Antihyperlipidemic) 1000 Mg Tbcr	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220845
Class 2	Duloxetine Hcl 30 Mg Cpep	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220846
Class 2	Duloxetine Hcl 60 Mg Cpep	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220996
Class 2	Minocycline Hcl Er 115 Mg Tb24	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=220904